INTRODUCTION
Indomethacin, a potent prostaglandin synthesis inhibitor, has been used as a tocolytic agent since 1974. 1 It is often effective in delaying delivery for 24 to 48 hours, the time needed to optimize antenatal corticosteroid use and benefit. 2 It suppresses preterm labor by interfering with prostaglandin-induced myometrial contractions. However, indomethacin also poses risks to both mother and fetus. Indomethacin has potent vasoconstrictor effects on a variety of fetal blood vessels, including the ductus arteriosus, and splanchnic and renal arteries. There is considerable evidence for an increased risk of adverse neonatal outcomes, including renal insufficiency (RI), in the infant exposed to maternal indomethacin use. 3 -8 There have been several reports of decreased renal function in the first days after birth in premature infants whose mothers received indomethacin for tocolysis. 5,6,9 -13,15 However, few of these publications addressed the length of time for which renal function remained abnormal. We noted that several premature infants in our neonatal intensive care unit (NICU) developed prolonged RI, lasting for weeks, following prenatal indomethacin exposure. As a result, we undertook a NICU-population-based examination of the risk of persistent RI in premature infants following the use of indomethacin for the suppression of preterm labor.
METHODS
Golisano Children's Hospital is part of a regional, tertiary referral center with approximately 4000 deliveries and 1200 NICU admissions per year. We limited our case-finding efforts to premature ( <34 weeks' gestation) infants whose mothers had received indomethacin and who were subsequently admitted to the NICU. We reviewed the NICU computerized database from January 1, 1994 through June 30, 1999 to identify infants in whom maternal indomethacin use was coded. We concurrently reviewed the hospital pharmacy database to determine which mothers received indomethacin for suppression of preterm labor. The pharmacy database included only the time period from October 1, 1997 to June 30, 1999.
Thirty-seven infants were identified whose mothers had received indomethacin for preterm labor and were subsequently admitted to the NICU. Of these, 23 were identified by both the NICU and pharmacy databases. We found 7 additional infants whose mothers received indomethacin (identified by the pharmacy database) and who were admitted to the NICU, but were not included in the NICU database. There were also 8 additional infants identified by the NICU database only; 7 of these were born before October 1, 1997 and 1 was born thereafter. All provisional cases were confirmed by chart review.
OBJECTIVE:
To determine the risk of persistent renal insufficiency ( RI ) in premature infants following the use of antenatal indomethacin for suppression of preterm labor.
STUDY DESIGN:
This population -based, retrospective review consisted of infants admitted during a 5 -year period ( 1994 -1999 ) to a tertiary referral neonatal intensive care nursery. Data were reviewed on 37 infants whose mothers received indomethacin for tocolysis, and on 37 matched controls. Renal insufficiency was defined as infant creatinine ( Cr ) 1.5 mg / dl ( 133 mol / l ) for 1 day.
RESULTS:
Infants whose mothers had received indomethacin for tocolysis were more likely than matched controls to have RI ( 9 of 37 vs 2 of 37, p = 0.04 ). Among infants of indomethacin -treated mothers with elevated Cr, serum Cr remained 1.5 mg / dl ( 133 mol / l ) for a median of 6 days and >1.0 mg / dl ( 88 mol / l ) for a median of 19 days. The peak Cr and length of elevation were closely correlated ( r 2 = 0.63, p < 0.0001 ).
Original Article
All infants' and mothers' charts were subsequently reviewed. The University of Rochester Institutional Review Board approved the study. The neonatal data obtained included sex, race, birth weight (BW), gestational age (GA), diagnoses, head ultrasound (HUS) results, feeding problems, doses of postnatal indomethacin, and survival. We specifically examined the infants' medical records for renal complications potentially associated with indomethacin exposure. These data included blood creatinine (Cr) levels, urine output (UOP), hematuria, urine electrolytes and Cr, gentamicin levels, and renal ultrasound (RUS) and imaging results.
The mothers' records were reviewed to determine the total number of doses of prenatal indomethacin administered, the duration of treatment with indomethacin, the length of time from the last dose of indomethacin to delivery of the infant(s), presence of oligohydramnios on prenatal ultrasound, preeclampsia during the pregnancy, and whether the mothers received treatment with other tocolytics.
Thirty-one of 37 case infants had at least one serum Cr level measured. It was assumed that the other 6 infants had normal Cr levels. We noted that, within this group, several infants (17 of 37) had at least one Cr level >1.0 mg/dl (88 mol/l). To determine if the elevated Cr levels were related to the antenatal indomethacin, a matched cohort of NICU infants born to mothers who did not receive indomethacin exposure was enrolled. The control group of infants were matched by gender, BW ( ±100 g), GA ( ±1 week), and year of birth. Controls were identified by the NICU database and all control infants' and mothers' charts were reviewed. Renal insufficiency was prospectively defined as having a serum Cr level above the 95th percentile identified in the control group of infants for 1 day.
Categorical variables were compared using two by two tables analyzed with the chi-square statistic for unpaired data or the McNemar statistic for paired data. Continuous variables were compared using the Student t-test and Mann-Whitney U test, as appropriate. The results are presented as mean±standard deviation unless otherwise specified. Backward selection multiple logistic regression was done to model the potential roles of various factors on the presence of RI ( Table 2 ). The model included GA, prenatal indomethacin, presence of preeclampsia, duration of dopamine, presence of asyphxia (defined as Apgar scores of <6 at 5 minutes of age), use of gentamicin for >48 hours, and postnatal indomethacin. p values below 0.05 were considered statistically significant.
RESULTS
Thirty-seven infant cases of antenatal indomethacin exposure were identified and matched to 37 control infants. Table 1 demonstrates the demographic characteristics of the two groups. Twenty-three infants (62%) were singletons, 10 infants (27%) were products of twin gestations, 3 infants (8%) were triplets, and 1 infant (3%) was a quadruplet (whose siblings died very shortly after birth before Cr levels were available).
The 37 indomethacin-exposed subjects were born to 30 mothers. The mean maternal age was 27±5 years. Mothers received a median of eight doses (range 1, 74) of indomethacin for suppression of preterm labor ( Figure 1 ). The median time from the last dose of indomethacin until delivery was 2 days (range 0, 136). One mother (3%) had preeclampsia. Twenty-five of the 30 mothers had prenatal ultrasound results recorded. Seven of those mothers (28%) had ultrasounds suggestive of oligohydramnios in the fetus. Fourteen mothers had Cr levels measured, all of which were within normal limits (0.7 to 1.1 mg/dl, 62 to 97 mol/l). 
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The 37 control subjects were born to 37 mothers. As expected, the 37 matched controls were similar to cases in BW, GA, and sex ratio. Thirty-one infants (84%) were singletons, 5 infants (14%) were products of twin gestations, and 1 infant (2%) was a triplet. Of the 37 control mothers, the mean maternal age was 29±6 years. Seven mothers had preeclampsia (19%). Thirty-one of the 37 mothers had prenatal ultrasound results recorded. Ten mothers (32%) had prenatal ultrasounds suggesting evidence of prenatal oligohydramnios in the fetus. Fourteen mothers had Cr levels measured, all of which were within normal limits.
Fourteen case infants (38%) and 15 control infants (41%) received postnatal indomethacin, either for treatment of a patent ductus arteriosus (PDA) or for prophylaxis of intraventricular hemorrhage (IVH). Thirty-three case infants (89%) and 35 (95%) controls survived to discharge from the NICU. A total of 27 case infants had an HUS performed and 11 of these (41%) had abnormal findings [GMH (germinal matrix hemorrhage) (5), grade II IVH (3), grade III IVH (1), grade IV IVH (2)]. Twenty-six control infants had an HUS performed and 9 of these (35%) had abnormal findings [GMH (5), grade II IVH (3), hydrocephalus (1)].
Two control infants (5%) had serum Cr1.5 mg/dl (133 mol/dl). This distribution fell within the ranges measured as elevated by others 5, 12, 13, 15 and was subsequently used to define RI. Nine (24%) case infants were identified as having RI with peak serum Cr 1.5 mg/dl (133 mol/l) ( p=0.04 for difference from controls) ( Table 1 ). However, the mean peak Cr did not vary between cases and controls (1.4±1.0 vs 1.1±0.2 mg/dl, p=0.18). UOP in all of the infants was normal (>1.0 ml/kg per hour). Fifteen case infants (6 with RI) and 10 control infants (2 with RI) were on dopamine for hypotension. Twenty case infants had RUS done, and 10 (50%) of these were abnormal [hydronephrosis grade I to II (6), echogenic kidneys (2), ischemic changes (1), decreased perfusion (2), and nephrocalcinosis (1)]. Five control infants had RUS done, and 4 (80%) of these were abnormal [hydronephrosis grade I to II (4)]. Of the 33 surviving case infants, 23 had no recognized renal concerns at the time of discharge from the NICU. The remaining 10 infants required either repeat renal imaging or continued renal function monitoring as outpatients. Two of the 35 surviving control infants had renal concerns at discharge.
Logistic regression was done to evaluate the potential role of various factors on the presence of RI (Table 2) . Preeclampsia, presence of asyphxia, use of gentamicin for >48 hours, and postnatal indomethacin dropped out of the analysis. When other variables were controlled, prenatal indomethacin use and duration of hypotension (as measured by number of days on dopamine) were associated with the presence of RI.
Cases and controls were equally likely to have at least one episode of feeding discontinuation for 1 feeding (66% vs 57%, p=0.15), but cases had a higher total number of episodes of feeding discontinuation than controls (Table 1) . Neither the likelihood of an abnormal HUS (41% of cases vs 35% of controls) nor survival was correlated with antenatal indomethacin exposure. Given that only 31 of the patients exposed to prenatal indomethacin had actually had Cr levels measured, a subanalysis of these 31 patients was performed. There were no changes in the patterns of any of the findings reported (data not shown).
We examined the cohort of children of indomethacin-exposed infants with RI more closely ( Table 3 ). All nine subjects with RI also had microscopic hematuria detected on at least five urine dipstick evaluations. Infants with RI were smaller and of younger gestation at birth (GA 26.7±1.3 weeks) than those without RI (28.6±2.4 weeks) ( p=0.03). By definition, the peak Cr level of infants with RI (2.4±1.3 mg/dl; 212±115 mol/l) were higher than those without RI (1.0±0.3 mg/dl; 88±27 mol/l). Infants with RI had elevated Cr, defined as 1.5 mg/dl (133 mol/l), for prolonged periods (median 6 days, range 1 to 33 days). Serum Cr remained >1.0 mg/dl (88 mol/l) for 1 week in 8 of 9 infants and 2 weeks in 5 of 9 infants (median 19 days, range 2 to 45 days). The peak Cr and length of elevation were closely correlated (r 2 =0.63, p<0.0001). The total number of indomethacin doses that the mother received was similar between groups. However, the number of days from the last dose of indomethacin until the day of delivery were longer in infants with RI (Table 3) .
Because several of the infants exposed antenatally to indomethacin had ceased receiving it weeks before delivery, the analysis was repeated including only infants with the final dose given 14 days (n=34 per group) and 7 days (n=31 per group) before birth and their controls. In both situations, the finding of markedly prolonged elevations of Cr in antenatal indomethacin recipients persisted.
Administration of postnatal indomethacin could potentate the effects of prenatal indomethacin exposure. However, we found no such effect. Only one child with RI had received >3 doses of postnatal indomethacin, and three had received no postnatal indomethacin whatsoever (Table 3) .
Five of 9 case infants with RI had abnormal RUS findings, [hydronephrosis grade I to II (4), echogenic kidneys (2), impaired perfusion (1), nephrocalcinosis (1)], all of which required continued follow-up or treatment at the time of NICU discharge. HUS, gentamicin levels, UOP, and survival were not correlated with RI (Table 3) .
DISCUSSION
Previous studies have demonstrated the benefit of using indomethacin as a tocolytic agent in the suppression of preterm labor.
1,2,14 Controversy exists regarding the risk of maternal indomethacin use to the fetus. Recent studies have confirmed a probable association between antenatal indomethacin exposure and adverse neonatal outcomes, including an increased incidence of neonatal mortality, respiratory distress syndrome (RDS), bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), focal intestinal perforation, persistent patent ductus arteriosus (PDA), intracranial hemorrhage, and RI. 3 -13,15 Our study demonstrates that antenatal indomethacin exposure may cause prolonged RI in some premature infants.
The effects of indomethacin on fetal and neonatal renal function are well recognized. 4 -8,10 -13,15 In adults, renal complications ranging from oliguria to acute renal failure have been associated with antiprostaglandin administration. Prostaglandins may maintain renal blood flow in adults by increasing renin production and by decreasing the local angiotensin II vasoconstrictive effect. Indomethacin has been shown to decrease plasma renin activity and urine flow. 13 It has potent vasoconstrictive effects on a variety of fetal blood vessels, including the renal arteries.
Maternal and fetal adverse effects usually resolve rapidly after discontinuation of indomethacin therapy, but may occasionally be persistent and severe. 6 In 1994, Nishikubo and colleagues 6 reported three cases of neonatal RI in very low birth weight infants following repeated antenatal administration of indomethacin to prevent labor. Three women received indomethacin (total dose of 150 to 850 g) for 3 to 14 days from admission to delivery. Oliguria, early onset of hyperkalemia and prolonged renal dysfunction occurred after birth in the infants. One infant had elevation of serum Cr levels for 21 days after birth; one infant on day of life 3 required peritoneal dialysis secondary to markedly elevated Cr levels; one infant had persistently elevated serum Cr levels during the first 9 days of life and subsequently died due to renal failure and sepsis on day of life 18. The authors concluded that antenatal administration of indomethacin close to delivery with extremely premature labor may cause renal impairment in very low birth weight infants. 6 Others later confirmed that maternal indomethacin treatment within 48 hours of birth suppressed renal function, causing neonatal elevations in Cr, depressed glomerular filtration rate (GFR), and in some cases, decreased urine production. 8, 9 These studies, however, did not address the duration of neonatal RI.
Our study supports previously described findings of an association between antenatal indomethacin exposure and postnatal renal dysfunction in preterm infants. 3, 4, 8 We found that infants whose mothers had received indomethacin for the suppression of labor were more likely to have RI than matched controls. Infants who developed elevated Cr also had other signs, such as hematuria, consistent with 
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Renal Insufficiency in Indomethacin-Exposed Infants renal injury. Moreover, when these infants developed RI, their serum Cr levels remained elevated for prolonged periods. As suggested by others, 2,3,9 these infants also had more frequent feeding intolerance than controls.
The half-life of indomethacin in preterm infants is at least double that in adults. 12 Heijden and colleagues 12 measured half-lives of indomethacin levels in premature infants. The half-life of indomethacin in preterm infants was up to 63 hours, implying that the effects of indomethacin prenatally could last for almost 1 week postnatally. Serum indomethacin levels varied from 0.1 to 1.9 g/ml within the first 6 hours of extrauterine life. This is the same range as that found when using indomethacin for medical closure of the PDA. They concluded that a significant decrease in GFR combined with a low UOP is present in neonates born after antenatal exposure to indomethacin. 12 Although the alteration in renal function may be transient, the very long half-life in the premature newborn, coupled with a further prolongation due to poor renal perfusion, could conceivably cause effects distant in time from the dose.
Indomethacin therapy for closure of a PDA in preterm neonates is responsible for transient RI. 16 Fourteen of our case infants received postnatal indomethacin either for closure of PDA or prevention of IVH. Six of those 14 case infants had RI, including 1 infant who received >3 doses of postnatal indomethacin. Guidelines in our unit protocol state that postnatal indomethacin is relatively contraindicated in patients with Cr >1.4 mg/dl (123 mol/l). Despite this, two cases received postnatal indomethacin when their Cr were >1.4 mg/dl (123 mol/l). Although postnatal indomethacin did not appear to correlate with the risk of RI, it could have prolonged the RI in these subjects.
RI was prospectively defined in our study as having serum Cr levels, for 1 day, above the 95th percentile (1.5 mg/dl, 133 mol/l) identified in the control group of infants. This level for the 95th percentile falls within the ranges measured by most other groups. 5, 12, 13, 15 Heijden et al. 12 compared serum Cr levels between indomethacin treated infants and controls between 28 and 34 weeks' gestation. Assuming a normal distribution of serum Cr values, the 97th percentile ( ±2 SD) for their control data would correspond to serum Cr levels between 0.9 and 1.0 mg/dl (80 to 88 mol/l) on day 2 to 4. Souter et al. 13 evaluated serum Cr levels 72 hours after birth. The 97th percentile for their data corresponded to a serum Cr level of 1.1 mg/dl (97 mol/l) in infants of 27 weeks' gestation. Norton et al. 5 examined serum Cr levels of infants 28±2 weeks' gestation on day of life 1 to 3. The 97th percentile for their data would be 1.2 to 1.6 mg/dl (106 to 141 mol/l). Lastly, Miall et al. 15 found mean peak serum Cr levels significantly higher than those reported by others, with means of 2.5 mg/dl (221 mol/l) for infants <27 weeks' gestation, 2.0 mg/dl (177 mol/l) for infants 27 to 29 weeks, and mean peak serum Cr levels of all subjects to be 1.9 mg/dl (168 mol/l).
We found that even very distant indomethacin exposure, weeks before delivery, was possibly associated with RI. This differs from the findings of Souter et al. 13 who showed that very low birth weight babies of <31 weeks' gestation who delivered within 48 hours of indomethacin exposure were more likely to have renal impairment as indicated by higher serum Cr levels at 72 hours of age. If confirmed by others, the finding of distant antenatal indomethacin effect could imply a long standing alteration of fetal renal perfusion persisting long after clearance of the drug from the fetomaternal circulation. Previous investigators have shown that indomethacin treatment given as a short course (the last 2 days of pregnancy) to pregnant women led to a significant functional impairment of the kidneys in their offspring, manifested as suppression of both GFR and urine production. In infants whose mothers received indomethacin, UOP was low (32.2±16.8 ml/day on day 1, increasing to 68.6±21.4 ml/day on day 4). This differed significantly from a control group who received no antenatal indomethacin (75.2±26.8 ml/day on day 1, increasing to 84.8±20.9 ml/day on day 4, p<0.001).
12 Unlike previous studies, we did not see any significant decrease in UOP associated with infants who had RI.
Despite our inability to demonstrate this association, indomethacin exposure in premature infants warrants close fluid, electrolyte and drug metabolism monitoring.
There are several areas in this retrospective evaluation in which ascertainment bias could influence the results. Although significant efforts were made to identify all neonates that were exposed to indomethacin antenatally, potentially not every single infant may have been identified. Furthermore, only 31 subjects whose mothers had received indomethacin had Cr levels checked. Although any method of accounting for the Cr levels of the remaining 6 cases has difficulties, including these cases as having normal Cr levels is the most conservative approach. Any other analysis would potentially artificially inflate the proportion of subjects with elevated Cr levels. In any case, a subanalysis including only the 31 subjects with available Cr levels did not lead to any alteration of our conclusions.
The RI group in this study was more premature and had lower birth weights than the non-RI group. Renal dysfunction, as evidenced by increased Cr levels, is more likely to occur in smaller, more premature infants. It has been demonstrated that, even in premature infants <32 weeks' gestation not exposed to antenatal indomethacin, Cr levels rise dramatically in the first 48 hours, reaching peak levels of up to 2.5 mg/dl (221 mol/l) before falling to equilibrium levels. 15 Peak plasma Cr levels are inversely related to GA and BW. Time to peak Cr concentration correlates inversely with gestation. Plasma Cr continues to rise for longer in the more preterm infants and may not fall until after 59 hours. 15 However, when infants of similar GA were compared in our study, prenatal indomethacin exposure remained an independent risk factor for RI.
Our findings indicate that antenatal exposure to maternal indomethacin for suppression of preterm labor can have significant, prolonged impact on the renal function of premature infants. Although our subjects did not have decreased UOP or need more frequent adjustment of renally excreted drugs, their serum Cr sometimes remained elevated for weeks, and several subjects required outpatient renal follow-up. We suggest close monitoring of fluid and electrolytes, Cr levels, UOP, and drug levels in all infants exposed to antenatal indomethacin. Avoidance of nephrotoxic drugs may be warranted until normal renal function resumes. Infants who do not resume normal renal function before discharge may require continued outpatient follow-up.
